60 Degrees Pharmaceuticals (SXTP) Competitors

$1.48 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$1.50 +0.02 (+1.01%)

As of 05/22/2026 06:43 PM Eastern

SXTP vs. INAB, CVKD, LIAN, LEXX, and MAAQ

Should you buy 60 Degrees Pharmaceuticals stock or one of its competitors? MarketBeat compares 60 Degrees Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 60 Degrees Pharmaceuticals include IN8bio (INAB), Cadrenal Therapeutics (CVKD), LianBio (LIAN), Lexaria Bioscience (LEXX), and Mana Capital Acquisition (MAAQ). These companies are all part of the "pharmaceutical products" industry.

How does 60 Degrees Pharmaceuticals compare to IN8bio?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Comparatively, 14.5% of IN8bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, 60 Degrees Pharmaceuticals had 6 more articles in the media than IN8bio. MarketBeat recorded 7 mentions for 60 Degrees Pharmaceuticals and 1 mentions for IN8bio. IN8bio's average media sentiment score of 0.00 beat 60 Degrees Pharmaceuticals' score of -0.80 indicating that IN8bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
60 Degrees Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
IN8bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

60 Degrees Pharmaceuticals presently has a consensus target price of $13.85, indicating a potential upside of 835.81%. IN8bio has a consensus target price of $4.00, indicating a potential upside of 139.52%. Given 60 Degrees Pharmaceuticals' higher possible upside, research analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

IN8bio has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%
IN8bio	N/A	-96.39%	-80.18%

60 Degrees Pharmaceuticals has a beta of 2.69, suggesting that its share price is 169% more volatile than the broader market. Comparatively, IN8bio has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market.

60 Degrees Pharmaceuticals has higher revenue and earnings than IN8bio. IN8bio is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	2.79	-$7.36M	-$8.92	N/A
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A

Summary

60 Degrees Pharmaceuticals beats IN8bio on 7 of the 13 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Cadrenal Therapeutics?

Cadrenal Therapeutics (NASDAQ:CVKD) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

In the previous week, 60 Degrees Pharmaceuticals had 6 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 7 mentions for 60 Degrees Pharmaceuticals and 1 mentions for Cadrenal Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.00 beat 60 Degrees Pharmaceuticals' score of -0.80 indicating that Cadrenal Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cadrenal Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
60 Degrees Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Cadrenal Therapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-411.03%	-275.61%
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%

60 Degrees Pharmaceuticals has higher revenue and earnings than Cadrenal Therapeutics. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A
60 Degrees Pharmaceuticals	$1.41M	2.79	-$7.36M	-$8.92	N/A

Cadrenal Therapeutics presently has a consensus price target of $13.00, indicating a potential upside of 150.48%. 60 Degrees Pharmaceuticals has a consensus price target of $13.85, indicating a potential upside of 835.81%. Given 60 Degrees Pharmaceuticals' higher possible upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Cadrenal Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cadrenal Therapeutics has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.69, indicating that its stock price is 169% more volatile than the broader market.

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 26.1% of Cadrenal Therapeutics shares are owned by insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

60 Degrees Pharmaceuticals beats Cadrenal Therapeutics on 9 of the 13 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to LianBio?

LianBio (NASDAQ:LIAN) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

74.8% of LianBio shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 7.6% of LianBio shares are owned by insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, 60 Degrees Pharmaceuticals had 7 more articles in the media than LianBio. MarketBeat recorded 7 mentions for 60 Degrees Pharmaceuticals and 0 mentions for LianBio. LianBio's average media sentiment score of 0.00 beat 60 Degrees Pharmaceuticals' score of -0.80 indicating that LianBio is being referred to more favorably in the media.

Company	Overall Sentiment
LianBio	Neutral
60 Degrees Pharmaceuticals	Negative

60 Degrees Pharmaceuticals has a consensus target price of $13.85, indicating a potential upside of 835.81%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than LianBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

LianBio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.69, suggesting that its stock price is 169% more volatile than the broader market.

LianBio has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat LianBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%

60 Degrees Pharmaceuticals has higher revenue and earnings than LianBio. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
60 Degrees Pharmaceuticals	$1.41M	2.79	-$7.36M	-$8.92	N/A

Summary

60 Degrees Pharmaceuticals beats LianBio on 8 of the 15 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Lexaria Bioscience?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

60 Degrees Pharmaceuticals has higher revenue and earnings than Lexaria Bioscience. Lexaria Bioscience is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	2.79	-$7.36M	-$8.92	N/A
Lexaria Bioscience	$710K	22.70	-$11.90M	-$0.47	N/A

In the previous week, 60 Degrees Pharmaceuticals had 6 more articles in the media than Lexaria Bioscience. MarketBeat recorded 7 mentions for 60 Degrees Pharmaceuticals and 1 mentions for Lexaria Bioscience. Lexaria Bioscience's average media sentiment score of 0.00 beat 60 Degrees Pharmaceuticals' score of -0.80 indicating that Lexaria Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
60 Degrees Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Lexaria Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

60 Degrees Pharmaceuticals has a net margin of -574.91% compared to Lexaria Bioscience's net margin of -1,685.84%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%
Lexaria Bioscience	-1,685.84%	-206.02%	-162.53%

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Comparatively, 8.4% of Lexaria Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

60 Degrees Pharmaceuticals currently has a consensus price target of $13.85, suggesting a potential upside of 835.81%. Lexaria Bioscience has a consensus price target of $1.50, suggesting a potential upside of 130.77%. Given 60 Degrees Pharmaceuticals' higher possible upside, equities analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Lexaria Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

60 Degrees Pharmaceuticals has a beta of 2.69, indicating that its share price is 169% more volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market.

Summary

60 Degrees Pharmaceuticals beats Lexaria Bioscience on 9 of the 14 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Mana Capital Acquisition?

Mana Capital Acquisition (NASDAQ:MAAQ) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

Mana Capital Acquisition has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%.

Company	Net Margins	Return on Equity	Return on Assets
Mana Capital Acquisition	N/A	N/A	N/A
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%

Mana Capital Acquisition has higher earnings, but lower revenue than 60 Degrees Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A
60 Degrees Pharmaceuticals	$1.41M	2.79	-$7.36M	-$8.92	N/A

In the previous week, 60 Degrees Pharmaceuticals had 7 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 7 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Mana Capital Acquisition. Mana Capital Acquisition's average media sentiment score of 0.00 beat 60 Degrees Pharmaceuticals' score of -0.80 indicating that Mana Capital Acquisition is being referred to more favorably in the media.

Company	Overall Sentiment
Mana Capital Acquisition	Neutral
60 Degrees Pharmaceuticals	Negative

68.4% of Mana Capital Acquisition shares are held by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

60 Degrees Pharmaceuticals has a consensus target price of $13.85, suggesting a potential upside of 835.81%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Mana Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mana Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

60 Degrees Pharmaceuticals beats Mana Capital Acquisition on 6 of the 10 factors compared between the two stocks.

Get 60 Degrees Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SXTP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SXTP vs. The Competition

Export

Metric	60 Degrees Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.94M	$3.04B	$6.46B	$12.34B
Dividend Yield	N/A	1.97%	2.76%	5.28%
P/E Ratio	-0.17	17.79	21.22	25.66
Price / Sales	2.79	336.21	562.28	86.31
Price / Cash	N/A	57.74	43.49	56.67
Price / Book	-0.82	5.86	10.31	7.14
Net Income	-$7.36M	$74.99M	$3.57B	$335.98M
7 Day Performance	4.96%	3.11%	6.43%	4.15%
1 Month Performance	-9.20%	-3.05%	3.57%	2.54%
1 Year Performance	-81.59%	34.38%	34.07%	35.06%

60 Degrees Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SXTP 60 Degrees Pharmaceuticals	2.7221 of 5 stars	$1.48 flat	$13.85 +835.8%	-81.6%	$3.94M	$1.41M	N/A	3
INAB IN8bio	3.2843 of 5 stars	$1.59 -0.6%	$4.00 +151.6%	-61.6%	$15.66M	N/A	N/A	20
CVKD Cadrenal Therapeutics	2.223 of 5 stars	$5.31 +2.3%	$13.00 +144.8%	-64.8%	$15.23M	N/A	N/A	4	Positive News
LIAN LianBio	N/A	$0.14 flat	N/A	-69.4%	$15.13M	N/A	N/A	110
LEXX Lexaria Bioscience	2.3498 of 5 stars	$0.60 +4.4%	$1.50 +149.0%	-40.9%	$14.93M	$710K	N/A	7	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SXTP) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

60 Degrees Pharmaceuticals (SXTP) Competitors

SXTP vs. INAB, CVKD, LIAN, LEXX, and MAAQ

How does 60 Degrees Pharmaceuticals compare to IN8bio?

Summary

How does 60 Degrees Pharmaceuticals compare to Cadrenal Therapeutics?

Summary

How does 60 Degrees Pharmaceuticals compare to LianBio?

Summary

How does 60 Degrees Pharmaceuticals compare to Lexaria Bioscience?

Summary

How does 60 Degrees Pharmaceuticals compare to Mana Capital Acquisition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTP vs. The Competition

60 Degrees Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

60 Degrees Pharmaceuticals (SXTP) Competitors

SXTP vs. INAB, CVKD, LIAN, LEXX, and MAAQ

How does 60 Degrees Pharmaceuticals compare to IN8bio?

Do institutionals & insiders have more ownership in SXTP or INAB?

Does the media favor SXTP or INAB?

Do analysts prefer SXTP or INAB?

Is SXTP or INAB more profitable?

Which has more volatility and risk, SXTP or INAB?

Which has higher earnings and valuation, SXTP or INAB?

Summary

How does 60 Degrees Pharmaceuticals compare to Cadrenal Therapeutics?

Does the media prefer CVKD or SXTP?

Is CVKD or SXTP more profitable?

Which has better valuation & earnings, CVKD or SXTP?

Do analysts recommend CVKD or SXTP?

Which has more volatility & risk, CVKD or SXTP?

Do insiders and institutionals believe in CVKD or SXTP?

Summary

How does 60 Degrees Pharmaceuticals compare to LianBio?

Do insiders and institutionals have more ownership in LIAN or SXTP?

Does the media prefer LIAN or SXTP?

Do analysts rate LIAN or SXTP?

Which has more risk and volatility, LIAN or SXTP?

Is LIAN or SXTP more profitable?

Which has preferable valuation and earnings, LIAN or SXTP?

Summary

How does 60 Degrees Pharmaceuticals compare to Lexaria Bioscience?

Which has higher valuation & earnings, SXTP or LEXX?

Does the media favor SXTP or LEXX?

Is SXTP or LEXX more profitable?

Do institutionals & insiders hold more shares of SXTP or LEXX?

Do analysts rate SXTP or LEXX?

Which has more volatility and risk, SXTP or LEXX?

Summary

How does 60 Degrees Pharmaceuticals compare to Mana Capital Acquisition?

Is MAAQ or SXTP more profitable?

Which has higher earnings & valuation, MAAQ or SXTP?

Does the media refer more to MAAQ or SXTP?

Do institutionals and insiders hold more shares of MAAQ or SXTP?

Do analysts recommend MAAQ or SXTP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTP vs. The Competition

60 Degrees Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools